文献速递青光眼

MINIject脉络膜上腔植入物治疗原发性开角型青光眼患者的两年性能与安全性结果:STAR-I、II、III试验的荟萃分析

Two-Year Performance and Safety Results of the MINIject Supraciliary Implant in Patients With Primary Open-Angle Glaucoma: Meta-Analysis of the STAR-I, II, III Trials.
PubMed 文献 · Am J Ophthalmol · 2023-12-16

该荟萃分析汇总了在6国11个中心开展的3项前瞻性、多中心、介入性、非随机试验(STAR-I、II、III),共82例原发性开角型青光眼患者接受MINIject脉络膜上腔引流装置作为独立手术。2年随访(n=66)时,日间眼压从基线23.8±3.3 mmHg降至14.4±4.5 mmHg(-39.3%;P<0.0001),89.4%患者眼压降幅≥20%,84.8%患者眼压≤18 mmHg。作者结论认为该装置在轻中度原发性开角型青光眼中展现出良好的安全性和有效性,是一种无滤过泡的治疗选择。

要点

  • 2年随访时平均眼压自基线23.8±3.3 mmHg降至14.4±4.5 mmHg(-39.3%;P<0.0001)。
  • 89.4%患者眼压降幅≥20%,84.8%患者眼压≤18 mmHg。
  • 降眼压药物从平均2.4±1.1种减至1.4±1.4种(P<0.0001),37.9%患者2年时无需药物。

核心结论

  • 该荟萃分析显示,在轻中度原发性开角型青光眼患者中以独立、内路手术方式植入脉络膜上腔装置具有良好的安全性和有效性。
  • 数据表明MINIject是一种安全有效、无滤过泡的治疗选择,适用于需要低目标眼压的患者,随访至2年。

研究设计与样本

  • 研究设计为荟萃分析,汇总3项前瞻性、多中心、介入性、非随机试验(STAR-I、II、III)的数据。
  • 研究在哥伦比亚、法国、德国、印度、巴拿马和西班牙的11个中心开展,共82例患者接受治疗。
  • 数据汇总分析随访至植入后2年,主要结局为日间眼压相对基线的平均相对和绝对降幅。

主要发现

  • 2年随访(n=66)时,平均眼压从基线23.8±3.3 mmHg降至14.4±4.5 mmHg(-39.3%;P<0.0001)。
  • 89.4%的患者眼压降幅≥20%,84.8%的患者眼压≤18 mmHg。
  • 降眼压药物从平均2.4±1.1种减少至1.4±1.4种(P<0.0001),37.9%的患者在2年时无需药物。
  • 2年时平均内皮细胞密度较基线丢失6.2±9.1%,无患者丢失>30%。

临床怎么用

  • 原文结论指出MINIject是一种安全有效、无滤过泡的治疗选择,适用于需要低目标眼压的轻中度原发性开角型青光眼患者,随访至2年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the performance and safety of minimally invasive glaucoma surgery with a supraciliary drainage device (MINIject; iSTAR Medical, Wavre, Belgium) in primary open-angle glaucoma (POAG) as a stand-alone procedure. DESIGN: Meta-analysis. METHODS: At 11 sites in Colombia, France, Germany, India, Panama, and Spain, 82 patients were treated in 3 prospective, multicenter, interventional, nonrandomized trials (STAR-I, II, III). Data were pooled in a meta-analysis of up to 2 years of follow-up postimplantation. The main outcome measures were mean relative and absolute reduction in diurnal intraocular pressure (IOP) compared to baseline. Secondary outcomes included patients with IOP ≤18 mmHg, patients with IOP reduction ≥20%, number of IOP-lowering medications, adverse events, and endothelial cell density loss. RESULTS: At the 2-year follow-up (n = 66), mean IOP was reduced from 23.8 ± 3.3 mmHg at baseline to 14.4 ± 4.5 mmHg (-39.3%; P < 0.0001). An IOP reduction of ≥20% was achieved in 89.4% of patients, with 84.8% having an IOP ≤18 mmHg. IOP-lowering medications were reduced from a mean of 2.4 ± 1.1 to 1.4 ± 1.4 (P < 0.0001), with 37.9% of patients being medication-free at 2 years. Mean endothelial cell density loss at 2 years was 6.2 ± 9.1% compared to baseline and no patient had a loss >30%. CONCLUSIONS: This meta-analysis demonstrates the favorable safety and efficacy profile of a supraciliary device implanted in a stand-alone, ab-interno procedure in patients with mild-to-moderate POAG. The data demonstrate that MINIject is a safe and effective, bleb-free treatment option for patients requiring low target IOP up to 2 years.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Dick HB, Mackert MJ, Ahmed IIK, et al. Two-Year Performance and Safety Results of the MINIject Supraciliary Implant in Patients With Primary Open-Angle Glaucoma: Meta-Analysis of the STAR-I, II, III Trials. Am J Ophthalmol. 2023. PMID: 38109951. doi:10.1016/j.ajo.2023.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。